Colorectal cancer (CRC) is the third leading cause of cancer death worldwide. The mainstay of treatment for advanced disease is chemotherapy combined with angiogenesis inhibitors and epidermal growth factor receptor (EGFR) inhibitors, but outcomes and toxicity are highly variable. Recent advances include combined small molecule/monoclonal antibody therapies for CRC with the V600E mutation in the BRAF gene for metastatic disease and immune checkpoint inhibition.
Browse our selection of video highlights and short articles from the conference hub, which provide insights into the latest updates from major conferences, and a collection of peer-reviewed articles from the journal portfolio. This is complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Our supporting partners do not constitute an endorsement of the content on this page.
The plenary session at the AACR Annual Meeting 2026 brought sharp focus to one of oncology’s most urgent challenges: the global rise in early-onset cancers. Across four complementary presentations, speakers combined epidemiology, molecular biology and clinical insight to frame a multifactorial, and still evolving, picture of risk in younger populations. Below, we have broken down the key points and take-home messages from the session.
Learn how RAS proteins play a crucial role in the regulation of cell proliferation and survival in normal cells. Oncogenic mutations in the RAS gene can drive cancer initiation and progression through disruption of this regulatory balance.
2025 has brought exciting developments in oncology, with groundbreaking research and real-world progress showcased at ASCO, ESMO, EHA, ASH and many more leading conferences around the world. We asked our key faculty to share what they believe has been most impactful so far this year – here’s what they told us.
Project Cure CRC, a $100 million initiative by the Colorectal Cancer Alliance (Alliance), continues to revolutionize colorectal cancer research by announcing three new groundbreaking grants aimed at transforming patient care. To date, Project Cure CRC has reviewed more than 500 research proposals and invested nearly $13 million to fuel 32 innovative studies. Several grantees have already published progress from their work in prestigious scientific journals, reflecting the program’s impact on advancing the field. As the largest nonprofit dedicated to ending colorectal cancer, the Alliance is prioritizing Project Cure CRC to accelerate the development of cutting-edge treatments that improve outcomes for patients worldwide.
The European Society for Medical Oncology (ESMO) 2025 congress brought over 100 late-breaking abstracts, 250 sessions, 600 expert speakers and 33,800 delegates to Berlin in October. The meeting highlighted innovations ranging from novel agents to real-world evidence and patient-centred care. In this article, hear from the experts on the key breakthroughs and clinical insights set to shape the future of oncology practice.
With the second half of 2025 underway, we asked our touchONCOLOGY Future Leaders 2025 to share the developments they believe will shape the future of the field. Here, they highlight five exciting areas that promise to transform practice – not only as the year draws to a close, but well into the future.
The first half of 2025 has brought exciting developments in oncology, with groundbreaking research and real-world progress showcased at ASCO, EHA and many more leading conferences around the world. We asked five of our touchONCOLOGY Future Leaders 2025 to share what they believe has been most impactful so far this year – here’s what they told us.
Project Cure CRC, the dynamic research initiative by the leading nonprofit Colorectal Cancer Alliance (Alliance), has awarded five new grants to advance urgent science in the colorectal cancer (CRC) space. To date, Project Cure CRC has received more than 400 research proposals and has invested almost $12 million in innovative colorectal cancer studies, with 29 grants funded. Project Cure CRC aims to accelerate and advance cutting-edge treatments to improve patient outcomes. As the largest nonprofit dedicated to ending this disease, the Alliance is prioritizing the initiative to help fill gaps from recent research funding cuts in the U.S.
Dr Frank Sinicrope presented results from the ATOMIC trial at #ASCO25, showing that adding atezolizumab to adjuvant FOLFOX halved the risk of recurrence or death in stage III dMMR colon cancer. With no major safety concerns, the findings support chemo-immunotherapy as a new standard of care for this patient group.
At #ASCO25, Dr Frank Sinicrope discussed major colon cancer trial updates, including ctDNA’s prognostic power post-surgery, the limitations of chemotherapy escalation in high-risk patients, and survival gains with first-line encorafenib + cetuximab + mFOLFOX6 in BRAF-mutant mCRC. These findings may reshape risk stratification and frontline treatment strategies.
At a time when cancer research is experiencing uncertainty and setbacks in America, the Colorectal Cancer Alliance (Alliance) is strengthening its commitment to its Project Cure CRC initiative because tomorrow can’t wait. Project Cure CRC funds cutting-edge colorectal cancer (CRC) research and aims to improve patient outcomes through its dynamic patient navigation portal, BlueHQ.org.
Dr Satish Nadig describes Northwestern Medicine’s first use of the RAPID procedure to treat metastatic colorectal cancer with liver transplantation. He outlines the innovative surgical techniques, the promise of the CLEAR program, and the future potential of machine perfusion technology to extend transplant opportunities to more patients.
Rare gastrointestinal (GI) cancers present unique challenges in diagnosis, treatment and research. Dr. Benjamin Weinberg discusses three of the rarest GI cancers: small bowel, appendix and anal cancer.
[embed]https://www.youtube.com/watch?v=Cd77dEeZfrc[/embed] As the leading nonprofit organization dedicated to ending the disease, the Colorectal Cancer Alliance (Alliance) continues to break boundaries in colorectal cancer care. Its Project Cure CRC research initiative ...
What’s new in GI oncology? With the 2025 ASCO Gastrointestinal Cancers Symposium still fresh in our minds, we hear from leading experts on the key abstracts and presentations from the conference in the fields of colorectal and pancreatic cancer. Circulating ...
It is with great pleasure that we present the latest edition of touchREVIEWS in Oncology & Haematology. This issue highlights the remarkable progress and innovation shaping the fields of oncology and haematology, featuring articles that delve into both emerging therapies ...
Keep track of your clinical interests and newsletter subscriptions.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Already registered? Login below.